Did IQVIA meet its financial performance in the fourth quarter of 2024?

The filing reports Q4 2024 revenue of $3,958 million, up 2.3 percent reported and 3.0 percent at constant currency. GAAP net income was $437 million, down 6.8 percent year-over-year, while Adjusted Net Income rose 7.8 percent to $564 million. Management described R&DS revenue as on target and TAS revenue as above target.

How strong were new business wins and backlog?

R&DS quarterly bookings were over $2.5 billion, with a book-to-bill ratio of 1.20x and a trailing-twelve-month ratio of 1.19x. Contracted backlog, including reimbursed expenses, was $31.1 billion, growing 4.4 percent year-over-year and 5.5 percent at constant currency. The company expects approximately $7.9 billion of this backlog to convert to revenue in the next twelve months.

What is the company's capital return and balance sheet position?

IQVIA repurchased $1,150 million of stock in Q4 and $1,350 million for the full year, and had $1,013 million of authorization remaining at year-end. On February 5, 2025, the board added $2,000 million, bringing the total to $3,013 million. At December 31, 2024, cash was $1,702 million, debt was $13,983 million, net debt was $12,281 million, and the Net Leverage Ratio was 3.33x.

What does the company expect for 2025?

IQVIA reaffirmed its 2025 outlook: constant-currency ex-COVID revenue growth of 4 to 7 percent, Adjusted EBITDA margin expansion of up to 20 basis points, and Adjusted Diluted EPS growth of 5 to 9 percent. Full-year revenue guidance is $15,725 million to $16,125 million, Adjusted EBITDA is $3,765 million to $3,885 million, and Adjusted Diluted EPS is $11.70 to $12.10. The guidance assumes just over $100 million of COVID-related revenue step-down, about 150 basis points of foreign exchange headwind, and 100 to 150 basis points of contribution from acquisitions.

Are the non-GAAP measures reconciled to GAAP?

Reconciliations for historical periods are included in the schedules attached to the release, covering Adjusted EBITDA, Adjusted Net Income, and Free Cash Flow. The company states that its full-year 2025 guidance, other than revenue, is given on a non-GAAP basis without a GAAP reconciliation, because certain items such as acquisition-related expenses, restructuring, and stock-based compensation cannot be predicted with reasonable certainty.

IQV 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed February 6, 2025. Cited figures are marked; the original filing is the authoritative source.

IQVIA Holdings Inc. filed this Form 8-K under Item 2.02 to furnish a press release reporting fourth-quarter and full-year 2024 results.

For the fourth quarter, revenue was $3,958 million^a, up 2.3 percent on a reported basis and 3.0 percent at constant currency. GAAP net income was $437 million and GAAP diluted EPS was $2.42, while Adjusted Diluted EPS was $3.12 and Adjusted EBITDA was $996 million. For the full year, revenue was $15,405 million, GAAP net income was $1,373 million, and Adjusted Diluted EPS was $11.13, up 9.1 percent.

Operating cash flow reached $2,716 million^b and free cash flow reached $2,114 million, up 26 percent and 41 percent year-over-year, respectively. The R&D Solutions segment booked over $2.5 billion in the quarter, a book-to-bill ratio of 1.20x, and ended the year with contracted backlog of $31.1 billion. The Technology & Analytics Solutions segment grew 9.5 percent at constant currency in the quarter and reached $6,160 million for the full year.

Net debt was $12,281 million^c, and the Net Leverage Ratio was 3.33x trailing twelve-month Adjusted EBITDA. The company repurchased $1,350 million of stock in 2024 and, on February 5, 2025, increased its repurchase authorization by $2,000 million to a total of $3,013 million. Management reaffirmed its 2025 outlook, including revenue guidance of $15,725 million to $16,125 million, Adjusted EBITDA of $3,765 million to $3,885 million, and Adjusted Diluted EPS of $11.70 to $12.10, with constant-currency ex-COVID revenue growth of 4 to 7 percent.

02—Key points

Key Highlights

Q4 2024 revenue of $3,958 million rose 2.3 percent on a reported basis; full-year revenue reached $15,405 million.
GAAP diluted EPS was $2.42 for Q4 and $7.49 for the full year; Adjusted Diluted EPS was $3.12 for Q4 and $11.13 for the full year.
TAS revenue grew 9.5 percent at constant currency in Q4 to $1,658 million, and reached $6,160 million for the full year.
R&DS quarterly bookings exceeded $2.5 billion, a 1.20x book-to-bill ratio, with contracted backlog of $31.1 billion.
Full-year operating cash flow was $2,716 million (up 26 percent) and free cash flow was $2,114 million (up 41 percent).
Net leverage ratio was 3.33x; the board increased the share repurchase authorization by $2,000 million to $3,013 million on February 5, 2025.
2025 guidance was reaffirmed, with revenue of $15,725 million to $16,125 million and Adjusted EBITDA of $3,765 million to $3,885 million.

03—Questions

Frequently Asked Questions

Did IQVIA meet its financial performance in the fourth quarter of 2024?
The filing reports Q4 2024 revenue of $3,958 million, up 2.3 percent reported and 3.0 percent at constant currency. GAAP net income was $437 million, down 6.8 percent year-over-year, while Adjusted Net Income rose 7.8 percent to $564 million. Management described R&DS revenue as on target and TAS revenue as above target.
How strong were new business wins and backlog?
R&DS quarterly bookings were over $2.5 billion, with a book-to-bill ratio of 1.20x and a trailing-twelve-month ratio of 1.19x. Contracted backlog, including reimbursed expenses, was $31.1 billion, growing 4.4 percent year-over-year and 5.5 percent at constant currency. The company expects approximately $7.9 billion of this backlog to convert to revenue in the next twelve months.
What is the company's capital return and balance sheet position?
IQVIA repurchased $1,150 million of stock in Q4 and $1,350 million for the full year, and had $1,013 million of authorization remaining at year-end. On February 5, 2025, the board added $2,000 million, bringing the total to $3,013 million. At December 31, 2024, cash was $1,702 million, debt was $13,983 million, net debt was $12,281 million, and the Net Leverage Ratio was 3.33x.
What does the company expect for 2025?
IQVIA reaffirmed its 2025 outlook: constant-currency ex-COVID revenue growth of 4 to 7 percent, Adjusted EBITDA margin expansion of up to 20 basis points, and Adjusted Diluted EPS growth of 5 to 9 percent. Full-year revenue guidance is $15,725 million to $16,125 million, Adjusted EBITDA is $3,765 million to $3,885 million, and Adjusted Diluted EPS is $11.70 to $12.10. The guidance assumes just over $100 million of COVID-related revenue step-down, about 150 basis points of foreign exchange headwind, and 100 to 150 basis points of contribution from acquisitions.
Are the non-GAAP measures reconciled to GAAP?
Reconciliations for historical periods are included in the schedules attached to the release, covering Adjusted EBITDA, Adjusted Net Income, and Free Cash Flow. The company states that its full-year 2025 guidance, other than revenue, is given on a non-GAAP basis without a GAAP reconciliation, because certain items such as acquisition-related expenses, restructuring, and stock-based compensation cannot be predicted with reasonable certainty.

04—Continue

← View all 8-K filings